Compare VECO & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VECO | NVCR |
|---|---|---|
| Founded | 1945 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | 1994 | 2015 |
| Metric | VECO | NVCR |
|---|---|---|
| Price | $31.72 | $14.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $28.00 | ★ $28.42 |
| AVG Volume (30 Days) | 593.3K | ★ 1.4M |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $681,408,000.00 | $642,269,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | $9.65 | $5.62 |
| P/E Ratio | $39.81 | ★ N/A |
| Revenue Growth | N/A | ★ 11.17 |
| 52 Week Low | $16.92 | $10.70 |
| 52 Week High | $34.45 | $29.80 |
| Indicator | VECO | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 56.20 | 70.16 |
| Support Level | $28.46 | $12.88 |
| Resistance Level | $29.58 | $13.64 |
| Average True Range (ATR) | 1.05 | 0.50 |
| MACD | 0.27 | 0.15 |
| Stochastic Oscillator | 60.29 | 97.47 |
Veeco Instruments Inc is a United States-based company engaged in designing, developing, and manufacturing thin-film process equipment, mainly used for producing electronic devices. The company focuses on semiconductor process equipment that addresses a range of challenging materials engineering problems for its customers. Its products include Laser Processing Systems, Lithography Systems, Ion Beam Systems, SiC CVD Systems, MOCVD Systems, Wet Processing Systems, MBE Technologies, Atomic Layer Deposition Systems, Physical Vapor Deposition Systems, Dicing and Lapping Systems, as well as Gas & Vapor Delivery Systems. The majority of the company's revenue is generated from sales to the Semiconductor Industry and within China.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.